Yopp A, Chen M, Cheng AL, Kaseb A, et al. Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma. J Hepatol 2026 Jan 22:S0168-8278(26)00017-6. doi: 10.1016/j.jhep.2026.
PMID: 41580093